Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

alt text

Join us as we explore how our Specific Productivity Optimization Technology aids us in increasing productivity in cell line development while maintaining high quality standards.

Innovative cell line and early process development are critical to generate high producing cell lines alongside a USP strategy to meet high quality standards. Improving productivity is often done by increasing VCD during USP, however this results in arduous clarification and elevated HCPs. Therefore, Polpharma Biologics developed SPOT™ technology to increase the cell line specific productivity (Qp), which facilitates high volumetric productivity at low VCD accompanied with a simple and efficient DSP process.

In this webninar, you will:

  • Learn how Specific Productivity Optimization Technology can increase cell line titers 150-300%
  • Discover how you can maintain quality and minimize undesired species while increasing cell line productivity


alt text

Dr Louis Boon

Chief Scientific Officer

Polpharma Biologics

Dr Boon received his Ph.D. in biochemistry at the University of Amsterdam. In 2003, he was one of the founders of Bioceros BV, now Polpharma Biologics, where he currently holds the position of CSO. In addition, he held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP preclinical for PanGenetics BV and Tanox. Dr Boon is an author of over 240 papers in international scientific journals in the field of medical biotechnology.

Moderated by

Maire Gerrard

Custom Content Writer

Informa Pharma Intelligence

Complete the form to watch the webinar on demand!

By completing this form you agree Polpharma Biologics may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.